relative to consumer protection, transparency, and oversight of certain health care transactions and establishing a study committee to analyze health insurance providers, their practices, policies, premiums, management, and the impact to consumers.
SB 666 would create a new regulatory framework for certain “material health care transactions” in New Hampshire, with a focus on transactions involving hospitals, clinics, physician practices, ambulatory surgical centers, urgent care centers, diagnostic facilities, and similar providers. The bill requires advance written notice to the Department of Justice at least 60 days before closing for transactions that involve a change of control, private equity entities, or for-profit health care entities. Those notices must include detailed disclosures about transaction structure, ownership and control, debt financing, planned distributions, and a market impact statement addressing competition, consumer costs, access, staffing, and service availability.
The bill gives the Department of Justice authority to review these transactions for likely effects on competition, prices, access, quality, continuity of care, and financial stability. After review, the department could prohibit a transaction if it is likely to substantially lessen competition or harm consumers, and it could also impose conditions such as limits on service reductions, staffing requirements, debt restrictions, or ongoing reporting. The bill also prohibits private equity entities, for-profit owners, and management services organizations from interfering with licensed clinicians’ independent medical judgment, and it creates enforcement tools including civil penalties, injunctive relief, divestiture or rescission, and treatment of violations as unfair or deceptive acts under the consumer protection law.
In addition to the transaction oversight provisions, SB 666 establishes a legislative study committee on private health insurers. The committee would examine insurers’ practices, policies, premiums, and management, and assess their effects on consumers, patients, coverage, care outcomes, and costs. The committee is required to report recommendations for policy or legislation by November 30, 2026. The bill’s main regulatory provisions would take effect July 1, 2027, while the study committee would begin immediately upon passage.
The overall sentiment reflected in the bill text is strongly consumer-protection oriented, with the stated purpose of preventing anticompetitive consolidation, excessive cost increases, and reduced access or quality of care. The bill is framed as a response to private equity and for-profit involvement in health care, and its title and findings language suggest a clear preference for stronger oversight and transparency. No committee transcript or vote record was provided, so there is no additional evidence of support, opposition, or amendments from legislative debate.
The main points of contention likely center on the scope of state oversight and the reach of the Department of Justice’s authority to review, condition, or block health care transactions. Health care providers, private equity firms, for-profit operators, and management services organizations may view the notice, disclosure, and control provisions as burdensome or as limiting investment and consolidation strategies, while supporters would likely argue that the bill is necessary to protect patients, preserve access, and prevent cost increases. The bill also raises potential debate over whether the state should regulate ownership and financing structures so directly, especially through consumer protection enforcement and restrictions on upstream distributions, debt, and operational control.
SB 666 would add a new chapter to the New Hampshire statutes governing material health care transactions and expand the Department of Justice’s role in reviewing health care mergers, acquisitions, affiliations, and other changes of control. It would require advance notice and extensive disclosures for covered transactions, authorize the department to review and potentially block or condition transactions, and make violations enforceable under the state consumer protection law. It also creates a new legislative study committee on private health insurers, which could lead to future legislation based on its findings.
The bill is presented in strongly protective terms, emphasizing consumer protection, transparency, competition, and preservation of access and clinical independence. Its framing suggests support for tighter oversight of private equity and for-profit health care ownership, as well as scrutiny of insurers. Because no committee discussion or votes were provided, there is no recorded legislative debate to indicate broader support or opposition, but the bill’s language clearly signals a reform-oriented, pro-regulation stance.
Likely areas of contention include whether the Department of Justice should have authority to review and potentially prohibit health care transactions, how broadly “material health care transaction” is defined, and whether the disclosure requirements are too intrusive for providers and investors. Private equity firms, for-profit health systems, management services organizations, and possibly some provider groups may object to restrictions on ownership, debt, dividends, and operational control, while supporters are likely to argue these tools are needed to prevent consolidation, price increases, and reduced access. The bill’s prohibition on interference with clinical judgment may also be debated as to how it applies in practice, especially where administrative oversight and utilization review overlap with clinical decision-making.